He is doing this by giving back to his family and being their for them and trying to go on in his normal routine. .
Pathophysiology.
Acute Myelogenous Leukemia (AML).
AML results from acquired (not inherited) genetic damage to the DNA of developing cells in the bone marrow. The effects are: 1) the uncontrolled, exaggerated growth and accumulation of cells called "leukemic blasts" which fail to function as normal blood cells and 2) the blockade of the production of normal marrow cells, leading to a deficiency of red cells (anemia), and platelets (thrombocytopenia) and normal white cells (especially neutrophils, i.e., neutropenia) in the blood. .
Causes and Risk Factors .
Older people are more likely to develop the disease. AML incidence increases dramatically among people who are over the age of 40. They are most prevalent in the sixth, seventh and eighth decades of life.
Subtypes of Acute Myelogenous Leukemia .
Leukemia is a malignant disease (cancer) of the bone marrow and blood. AML can occur in a variety of ways; different types of cells may be seen by the physician in blood or marrow. Since most patients have one of seven different patterns of blood cell involvement, these patterns have formed a subclassification. Myeloblasts are undeveloped cells. If they are the dominant leukemic cells in the marrow at the time of diagnosis the leukemia is referred to as "myeloblastic" type. If there are many myeloblasts but there are some cells developing towards fully formed blood cells, the added designation "with maturation" is used. If there are cells that are developing features of monocytes ("monocytic" type) or red cells ("erythroleukemic"), these designations are used and so forth. Even though the leukemia cells look somewhat like blood cells, the process of their formation is incomplete. .
The subclassification of the disease is important. Different types of therapy may be used and the likely course of the disease may be different.
